The staging of renal cell carcinoma

Current Opinion in Urology

Volumn 18, Issue 5, 2008, Pages 455-461

  Shuch, Brian ^a   La Rochelle, Jeff C ^a   Pantuck, Allan J ^a   Belldegrun, Arie S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Metastasis system; Nodes; Prognosis; Renal cell carcinoma; Staging; Tumor

Indexed keywords

ACCURACY; ALGORITHM; CANCER LOCALIZATION; CANCER SIZE; CANCER STAGING; DECISION MAKING; DISEASE SEVERITY; HUMAN; KIDNEY CARCINOMA; LYMPH NODE DISSECTION; METASTASIS; NEPHRECTOMY; NOMOGRAM; PATIENT COUNSELING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; VALIDATION PROCESS; KIDNEY; KIDNEY TUMOR; PATHOLOGY;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY; KIDNEY NEOPLASMS; NEOPLASM STAGING;

EID: 54549121429     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32830a4f36     Document Type: Review

References (79)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Hollingsworth JM, Miller DC, Daignault S, et al. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 2006; 98:1331-1334.
3. Chow WH, Devesa SS, Warren JL, et al. Rising incidence of renal cell cancer in the United States. JAMA 1999; 281:1628-1631.
4. DevCan. Probability of Developing or Dying of Cancer Software, Version 6.2.1. Maryland, USA: Statistical Research and Applications Branch, National Cancer Institute; 2007.
5. Cancer Statistics 2008 Presentation. Georgia, USA: American Cancer Society; 2008.
6. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001; 166:1611-1623.
7. Janzen NK, Kim HL, Figlin RA, et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003; 30:843-852.
8. Piltz S, Meimarakis G, Wichmann MW, et al. Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg 2002; 73:1082-1087.
9. van der Poel HG, Roukema JA, Horenblas S, et al. Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. Eur Urol 1999; 35:197-203.
10. Sandhu SS, Symes A, A'Hern R, et al. Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma. BJU Int 2005; 95:522-525.
11. Bruno JJ 2nd, Snyder ME, Motzer RJ, et al. Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival. BJU Int 2006; 97:933-938.
12. Hewitt M, Rowland JH. Mental health service use among adult cancer survivors: analyses of the National Health Interview Survey. J Clin Oncol 2002; 20:4581-4590.
13. Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008; 53:917-930.
14. Flocks RH, Kadesky MC. Malignant neoplasms of the kidney; an analysis of 353 patients followed five years or more. J Urol 1958; 79:196-201.
15. RobsonCJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969; 101:297-301.
16. Siminovitch JM, Montie JE, Straffon RA. Prognostic indicators in renal adenocarcinoma. J Urol 1983; 130:20-23.
17. Harmer M. TNM classification of malignant tumors. 3rd ed. Geneva: International Union Against Cancer; 1974.
18. Hermanek P, Sobin LH. TNM classification of malignant tumours. 4th ed. Berlin: Springer-Verlag; 1987.
19. Manual for staging of cancer. Philadelphia, Pennsylvania, USA: J.B. Lippincott; 1992.
20. Guinan P, Sobin LH, Algaba F, et al. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997; 80: 992-993.
21. American Joint Committee on Cancer. Kidney. New York: Springer; 2002.
22. Frank I, Blute ML, Leibovich BC, et al. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 2005; 173:1889-1892.
23. Ficarra V, Schips L, Guille F, et al. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer 2005; 104:968-974.
24. Hafez KS, FerganyAF, NovickAC. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 1999; 162:1930-1933.
25. LernerSE, Hawkins CA, Blute ML, et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol 1996; 155:1868-1873.
26. Zisman A, Pantuck AJ, Chao D, et al. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7cm better correlates with clinical outcome. J Urol 2001; 166:54-58.
27. ChevilleJC, Blute ML, Zincke H, et al. Stage pT1 conventional (clear cell) renal cell carcinoma: pathological features associated with cancer specific survival. J Urol 2001; 166:453-456.
28. Ficarra V, Guille F, Schips L, et al. Proposal for revision of the TNM classification system for renal cell carcinoma. Cancer 2005; 104:2116-2123.
29. Kinouchi T, Saiki S, Meguro N, et al. Impact of tumor size on the clinical outcomes of patients with Robson State I renal cell carcinoma. Cancer 1999; 85:689-695.
30. Tsui KH, Shvarts O, Smith RB, et al. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol 2000; 163:426-430.
31. Frank I, Blute ML, Leibovich BC, et al. pT2 classification for renal cell carcinoma. Can its accuracy be improved? J Urol 2005; 173:380-384.
32. Lam JS, Klatte T, Patard JJ, et al. Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol 2007; 52:155-162.
33. Ficarra V, Galfano A, Guille F, et al. A new staging system for locally advanced (pT3-4) renal cell carcinoma: a multicenter European study including 2,000 patients. J Urol 2007; 178:418-424; discussion 423-424.
34. Klatte T, Pantuck AJ, Riggs SB, et al. Prognostic factors for renal cell carcinoma with tumor thrombus extension. J Urol 2007; 178:1189-1195; discussion 1195.
35. Thompson RH, Cheville JC, Lohse CM, et al. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer 2005; 104:53-60.
36. Margulis V, Tamboli P, Matin SF, et al. Redefining pT3 renal cell carcinoma in the modern era: a proposal for a revision of the current TNM primary tumor classification system. Cancer 2007; 109:2439-2444.
37. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20:4559-4566.
38. Kattan MW, Reuter V, Motzer RJ, et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001; 166:63-67.
39. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005; 173:48-51.
40. Karakiewicz PI, Briganti A, Chun FK, et al. Multiinstitutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 2007; 25:1316-1322.
41. Han KR, Bui MH, Pantuck AJ, et al. TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J Urol 2003; 169:899-903; discussion 903-904.
42. Leibovich BC, Cheville JC, Lohse CM, et al. Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved? J Urol 2005; 173:716-719.
43. Thompson RH, Leibovich BC, Cheville JC, et al. Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified aspT3a? J Urol 2005; 173:918-921.
44. Thompson RH, Leibovich BC, Cheville JC, et al. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? J Urol 2005; 174:1218-1221.
45. Margulis V, Tamboli P, Matin SF, et al. Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma. J Urol 2007; 178:1878-1882.
46. Kim HL, Zisman A, Han KR, et al. Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol 2004; 171:588-591.
47. Moinzadeh A, Libertino JA. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? J Urol 2004; 171:598-601.
48. Blute ML, Leibovich BC, Lohse CM, et al. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int 2004; 94:33-41.
49. Haferkamp A, Bastian PJ, Jakobi H, et al. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup. J Urol 2007; 177:1703-1708.
50. Klaver S, Joniau S, Suy R, et al. Analysis of renal cell carcinoma with subdiaphragmatic macroscopic venous invasion (T3b). BJU Int 2008; 101:444-449.
51. Lambert EH, Pierorazio PM, Shabsigh A, et al. Prognostic risk stratification and clinical outcomes in patients undergoing surgical treatment for renal cell carcinoma with vascular tumor thrombus. Urology 2007; 69:1054-1058.
52. Tsui KH, Shvarts O, Smith RB, et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000; 163:1090-1095; quiz 1295.
53. Margulis V, Sanchez-Ortiz RF, Tamboli P, et al. Renal cell carcinoma clinically involving adjacent organs: experience with aggressive surgical management. Cancer 2007; 109:2025-2030.
54. Waters WB, Richie JP. Aggressive surgical approach to renal cell carcinoma: review of 130 cases. J Urol 1979; 122:306-309.
55. Blom JH, van Poppel H, Marechal JM, et al. Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol 1999; 36:570-575.
56. Siminovitch JP, Montie JE, Straffon RA. Lymphadenectomy in renal adenocarcinoma. J Urol 1982; 127:1090-1091.
57. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 2003; 97:2995-3002.
58. Vasselli JR, Yang JC, Linehan WM, et al. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol 2001; 166:68-72.
59. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 2003; 169:2076-2083.
60. Terrone C, Cracco C, Porpiglia F, et al. Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol 2006; 49:324-331.
61. Karakiewicz PI, Trinh QD, Bhojani N, et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol 2007; 51:1616-1624.
62. Joslyn SA, Sirintrapun SJ, Konety BR. Impact of lymphadenectomy and nodal burden in renal cell carcinoma: retrospective analysis of the National Surveillance, Epidemiology, and End Results database. Urology 2005; 65:675-680.
63. Hollenbeck BK, Ye Z, Wong SL, et al. Hospital lymph node counts and survival after radical cystectomy. Cancer 2008; 112:806-812.
64. Canfield SE, Kamat AM, Sanchez-Ortiz RF, et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol 2006; 175:864-869.
65. Margulis V, Tamboli P, Matin SF, et al. Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma. Cancer 2008; 112:1480-1488.
66. Shvarts O, Lam JS, Kim HL, et al. Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans. J Urol 2004; 172:867-870.
67. Shuch B, La Rochelle B, Klatte T, et al. Brain metastasis from renal cell carcinoma: presentation, recurrence, survival, and implications for systemic therapy. Cancer (in press).
68. Mani S, Todd MB, Katz K, et al. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 1995; 154:35-40.
69. Seaman E, Goluboff ET, Ross S, et al. Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma. Urology 1996; 48:692-695.
70. Leibovich BC, Cheville JC, Lohse CM, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 2005; 174:1759-1763; discussion 1763.
71. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23:832-841.
72. Han KR, Pantuck AJ, Bui MH, et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 2003; 61:314-319.
73. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168:2395-2400.
74. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988; 48:7310-7313.
75. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17:2530-2540.
76. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001; 19:1649-1657.
77. Slaton JW, Zisman A, Belldegrun A, et al. Validation of UCLA Integrated Staging System (UISS) as a predictor for survival in patients undergoing nephrectomy for renal cell carcinoma. J Urol 2002; 167:192.
78. Han KR, Bleumer I, Pantuck AJ, et al. Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. J Urol 2003; 170:2221-2224.
79. Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004; 22:3316-3322.